Advances on erythropoietin treatment of anemia in prematurity infants
10.3760/cma.j.issn.2095-428X.2019.23.019
- VernacularTitle: 促红细胞生成素治疗早产儿贫血研究进展
- Author:
Silu WANG
1
;
Xiaotian XIE
Author Information
1. Department of Pediatrics, Tongji Hospital of Tongji University(Shanghai Tongji Hospital), Shanghai 200065, China
- Publication Type:Review
- Keywords:
Erythropoietin;
Anemia;
Infant, preterm;
Erythropoiesis stimulating agent;
Darepoetin alfa;
Treatment
- From:
Chinese Journal of Applied Clinical Pediatrics
2019;34(23):1831-1833
- CountryChina
- Language:Chinese
-
Abstract:
Anemia is one of the common complications in preterm infants.Although there are many factors that can cause anemia of prematurity (AOP), erythropoietin (EPO) deficiency is one of the main causes of AOP.Insufficient EPO levels in premature infants and their mechanisms are the hotspots of AOP research at home and abroad.The rational use of EPO for prevention and treatment of AOP has become an international consensus and significant clinical outcomes have been obtained.The recent progress in the field of AOP, the relationship between EPO and AOP, and the clinical application and efficacy of EPO in the prevention and treatment of AOP in recent 3 to 5 years have been reviewed.
